Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
January 02 2019 - 7:00AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company) announced today that Seth Lederman, M.D., President and
Chief Executive Officer of Tonix, will present a company overview
at two investor conferences in January 2019.
In addition, Dr. Lederman will participate in a panel during the
2nd Annual Neuroscience Innovation Forum titled, “Advances in
Neuropsychiatry and Pain Management,” scheduled from 11:10 a.m. –
11:45 a.m. ET, January 6, 2019, in Room Commandants.
Details of the Tonix Pharmaceuticals company presentations and
webcasts are as follows:
Event: |
|
2nd Annual Neuroscience Innovation Forum |
Date: |
|
Sunday, January 6, 2019 |
Time: |
|
6:45 p.m. ET (3:45 p.m. PT) |
Location: |
|
Marines’ Memorial Club & Hotel, San Francisco
(Room Commandants) |
|
|
|
Event: |
|
Biotech Showcase |
Date: |
|
Tuesday, January 8, 2019 |
Time: |
|
6:00 p.m. ET (3:00 p.m. PT) |
Location: |
|
Hilton San Francisco Union Square (Franciscan A,
Ballroom Level) |
About Tonix Pharmaceuticals Holding Corp.
A live webcast and subsequent archived recording of the Company
presentations will be available under the IR Events tab of the
Investor Relations section of the Tonix Pharmaceuticals website at
www.tonixpharma.com.
Tonix is a clinical-stage biopharmaceutical company focused on
discovering and developing pharmaceutical products to treat serious
neuropsychiatric conditions and biological products to improve
biodefense through potential medical counter-measures. Tonix is
developing Tonmya®*, which is in Phase 3 development and has been
granted Breakthrough Therapy designation by the FDA, as a bedtime
treatment for PTSD. Tonix is also developing TNX-102 SL as a
bedtime treatment for agitation in Alzheimer’s disease under a
separate IND to support a Phase 2, potential pivotal, efficacy
study and has been designated a Fast Track development program by
the FDA for this indication. TNX-601 (tianeptine oxalate) is
in the pre-IND application stage, also for the treatment of PTSD
but by a unique mechanism and designed for daytime dosing. Phase 1
clinical study of TNX-601 in healthy volunteers will be conducted
outside of the U.S. in 2019. Tonix’s lead biologic candidate,
TNX-801, is a potential smallpox-preventing vaccine based on a live
synthetic version of horsepox virus, currently in the pre-IND
application stage.
*Tonmya has been conditionally accepted by the U.S. Food and
Drug Administration (FDA) as the proposed trade name for TNX-102 SL
(cyclobenzaprine HCl sublingual tablets) for the treatment of PTSD.
TNX-102 SL is an investigational new drug and has not been approved
for any indication.
This press release and further information about Tonix can be
found at www.tonixpharma.com.
Forward Looking
Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Tonix's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of
government or third party payor reimbursement; limited research and
development efforts and dependence upon third parties; and
substantial competition. As with any pharmaceutical under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. Tonix
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in the Annual Report on Form 10-K for the year ended
December 31, 2017, as filed with the Securities and Exchange
Commission (the “SEC”) on March 9, 2018, and periodic reports filed
with the SEC on or after the date thereof. All of Tonix's
forward-looking statements are expressly qualified by all such risk
factors and other cautionary statements. The information set forth
herein speaks only as of the date thereof.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(212) 980-9159
Scott Stachowiak (media)Russo
Partnersscott.stachowiak@russopartnersllc.com (646) 942-5630
Peter Vozzo (investors)Westwicke
Partnerspeter.vozzo@westwicke.com (443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024